BioViva USA Inc., a biotechnology company, has been granted US Patent No. 12,653,907 for its innovative approach to treating age-related disorders. The patent, issued on June 16, 2026, covers methods combining human telomerase reverse transcriptase (hTERT) and Follistatin-344 (FST) to target aging mechanisms. This breakthrough is part of BioViva’s broader mission to develop genetic therapies that address the root causes of aging, rather than merely treating symptoms.
Aging Biology in Focus
The patented technology targets two key players in aging: hTERT, which maintains telomeres—protective chromosome caps linked to cellular aging—and Follistatin-344, a protein influencing muscle and tissue function. hTERT, as the catalytic component of telomerase, plays a critical role in preserving telomere length, which is essential for cellular replicative capacity. Follistatin-344 is involved in biological pathways associated with muscle and tissue function.
BioViva’s strategy focuses on the underlying biology of aging, rather than treating individual age-related diseases. BioViva’s approach is based on the premise that many chronic diseases of later life share biological processes that develop over decades. Rather than waiting until those diseases become clinically apparent, BioViva is investigating whether genetic interventions directed at underlying biological mechanisms can become part of a broader strategy for maintaining human health and function.
Read Also: Government launches fund to boost biotech growth
Patent Details and Implications
The patent covers combination therapies involving hTERT and Follistatin-344, with claims related to telomere length, muscle mass, and blood-glucose levels. It also includes genetic delivery methods, such as using adeno-associated virus (AAV) vectors. The patent’s scope extends to various administration routes and formulations, providing a robust foundation for future clinical development.
This addition strengthens BioViva’s intellectual property portfolio, which already includes genetic interventions for aging and age-related diseases. The company’s research spans telomere maintenance, tissue regeneration, metabolic regulation, and cognitive decline. The patent complements BioViva’s existing intellectual property around genetic interventions for aging and age-related disease.
BioViva’s CEO, Elizabeth Parrish, stated, “This patent represents an important milestone in BioViva’s effort to develop a new category of medicine focused on the biology of aging.” The company aims to shift medical focus from treating diseases to addressing the biological mechanisms of aging. Parrish emphasized that this patent is a sign of years of dedicated research and a validation of BioViva’s unique approach to aging. The company’s long-term vision is to transform the way society approaches health and longevity, moving from reactive disease management to proactive health maintenance.
Read Also: Panel urges health ministry to study Ayush drug costs
A New Paradigm for Aging
Modern medicine has achieved remarkable advances by treating individual diseases. BioViva’s approach is based on the premise that many chronic diseases of later life share biological processes that develop over decades. Rather than waiting until those diseases become clinically apparent, BioViva is investigating whether genetic interventions directed at underlying biological mechanisms can become part of a broader strategy for maintaining human health and function.
The patent reflects BioViva’s commitment to developing advanced genetic and regenerative therapies for aging-associated conditions. As Parrish noted, “Aging is the greatest risk factor for many of the diseases that ultimately limit human healthspan.” With this patent, BioViva continues to pioneer a new paradigm in medicine, one that addresses the root causes of age-related decline rather than merely managing its consequences.
